Saint Vincent and the Grenadines

Pharmacovigilance in Saint Vincent and the Grenadines is coordinated by the Ministry of Health through the Pharmacovigilance and Drug Information Centre, established within Government Pharmaceutical Services. The Centre collects suspected adverse reactions to medicines and vaccines from the public and private sectors and transmits national safety information through the regional VigiCarib mechanism. Saint Vincent and the Grenadines became a full member of the WHO Programme for International Drug Monitoring in 2020. The Ministry’s official reporting guidance asks for reports of serious events, unexpected reactions, therapeutic failures, medication or device use errors, and product-quality problems as soon as a medicine-related negative effect is suspected; an official suspected adverse-drug-reaction form is also available. Public sources do not define blanket local-QPPV, PSMF, or periodic-reporting duties for every MAH, so companies should confirm product-specific expectations, maintain documented safety oversight, and ensure rapid communication of significant risks and recalls. Where the cited public sources do not expressly define periodic safety reporting, risk-management plan, signal management and audit and inspection arrangements, the MAH should confirm the current product-specific requirements with the competent authority and against the marketing-authorisation conditions. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.